Public Market Listing
Live quotes, historical charts, and market capitalization for Haisco Pharmaceutical Group are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(8 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Kappa-opioid receptor (agonist, peripherally restricted)Peptide | Chronic Kidney Disease | |
| Phase 3 | DPP-4Small molecule | Type 2 Diabetes | |
| Phase 3 | α2δ-1 subunit of voltage-gated calcium channelsSmall molecule | Diabetic Peripheral Neuropathic Pain | |
| Phase 3 | Phosphodiesterase 3 and Phosphodiesterase 4 (PDE3/PDE4)Small molecule | Chronic Obstructive Pulmonary Disease | |
| Phase 3 | PDE4BSmall molecule | Atopic DermatitisPsoriasisIdiopathic Pulmonary Fibrosis | |
| Phase 2 | IL-23 receptorPeptide | Inflammatory Bowel DiseasePsoriasis Ulcerative Colitis | |
| Phase 1 | EGFRSmall molecule | Non-Small Cell Lung Cancer | |
| Phase 1 | PRMT5Small molecule | Non-Small Cell Lung CancerPancreatic Ductal Adenocarcinoma |
Upcoming events
(11 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $231M | $33M | $267M | — | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q3 | $461M | $76M | $197M | — | report ↗ |
| 2025-H1 | $276M | $47M | $203M | — | report ↗ |
| 2024-Q3 | $384M | $53M | $115M | — | report ↗ |
| 2024-H1 | $234M | $30M | $148M | — | report ↗ |
| 2024-Q1 | $105M | $12M | $201M | — | report ↗ |
| 2023-Q3 | $330M | $38M | $121M | — | report ↗ |
| 2023-H1 | $198M | $30M | $166M | — | report ↗ |
| 2023-Q1 | $91M | $13M | $163M | — | report ↗ |
| 2022-Q3 | $306M | $34M | $80M | — | report ↗ |
| 2022-H1 | $193M | $28M | $159M | — | report ↗ |
| 2022-Q1 | $89M | $11M | $95M | — | report ↗ |
| 2021-Q3 | $295M | $44M | $83M | — | report ↗ |
| 2021-H1 | $197M | $26M | $128M | — | report ↗ |
| 2021-Q1 | $112M | $14M | $150M | — | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $611M | $112M | $198M | — | report ↗ |
Haisco Pharmaceutical Group reported revenue of $610.87M, up 17.9% YoY, R&D spend of $111.97M, up 28.9% YoY, and cash and equivalents of $198.03M for fiscal year 2025.
Figures only: this period's report disclosed no narrative text